Estrella Immunopharma, Inc. (ESLA)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$1.9M
Cash & Equivalents
$6.7M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$40M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-31 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06343311 T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) PHASE2 Recruiting 21

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ESLA.

SEC EDGAR Filings

All SEC filings for Estrella Immunopharma, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.